Pasithea Therapeutics Corp. KTTA 深 滬
等待開盤 09-23 09:30:00 美东时间
0.7216
-0.011
-1.57%
華盛通- 最 高0.73
- 今 開0.73
- 成交量 3.42万股
- 最 低 0.709
- 昨 收 0.7331
- 總市值 537.13万
- 52周最高 6.07
- 市盈率 靜 --
- 換手率 0.46%
- 52周最低 0.65
- 委 比 -33.33%
- 總股本 744.36万
- 歷史最高 170.00
- 量 比 0.27
- 振 幅 2.86%
- 歷史最低 0.65
- 每 手 1
- 風險率 1.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多External Safety Review Committee Recommended Pasithea Therapeutics' Phase 1/1b Study To Assess PAS-004 For Neurofibromatosis Type 1 To Proceed To Cohort 2, 8mg Tablet, Without Modification, Initial Interim Data From First Two Cohorts Expected In Q1 2026
Recommendation that trial escalate to next dose level of 8mg tablet --Initial interim clinical data from first two cohorts expected in Q1 2026
09-08 19:08
Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Pasithea Therapeutics Corp. announced that its CEO, Dr. Tiago Reis Marques, will present at the H.C. Wainwright Global Investment Conference in New York City on September 10, 2025. The company, which is developing the MEK inhibitor PAS-004, is currently conducting Phase 1 clinical trials for advanced cancer and neurofibromatosis type 1.
08-28 11:02
Pasithea Therapeutics Q2 EPS $(0.66) Up From $(3.71) YoY
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.66) per share. This is a 82.21 percent increase over losses of $(3.71) per share from the same period last year.
08-15 05:55
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Pasithea Therapeutics Corp. has completed enrollment and initial dosing of three subjects in Cohort 1 of its Phase 1/1b clinical trial evaluating PAS-004, a next-generation MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) in adults with plexiform neurofibromas. The trial aims to assess safety, tolerability, and preliminary efficacy. PAS-004, administered once daily, may offer improved patient compliance compared to current thera...
07-31 11:01
Pasithea Therapeutics Faces Nasdaq Delisting Notice
An announcement from Pasithea Therapeutics Corp ( ($KTTA) ) is now available. O...
06-28 04:41
Kratos Defense & Security Solutions, Inc. Prices Public Offering of Common Stock
<p>Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) has priced an underwritten offering of 12,987,013 shares of its common stock at $38.50 per share, with net proceeds expected to be approximately $483.75 million. The company has granted underwriters a 30-day option to purchase up to an additional 1,948,052 shares. Proceeds will be used to fund investments in national security programs, targeted acquisitions, and general corporate purpose...
06-26 03:14
Pasithea Therapeutics Expands Stock Offering Limit
The latest update is out from Pasithea Therapeutics Corp ( ($KTTA) ). On June 2...
06-21 04:59
Pasithea Adds Drug Expert Dr. James Lee To Guide New Treatment For Crohn's And Other Inflammatory Diseases
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr.
06-11 19:22
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
Pasithea Therapeutics Corp. has appointed Dr. James Lee to its scientific advisory board to guide the development of PAS-004 for treating ETS2-driven inflammatory diseases, including IBD, ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis, and ankylosing spondylitis. Dr. Lee, a leading expert in IBD and a clinician scientist at the Francis Crick Institute, published a 2024 study in Nature identifying ETS2 as a key regulator of ma...
06-11 11:02
Pasithea Announces Its PAS-004 Shows Early Activity And Durable Disease Stability In Heavily Pretreated Solid Tumors, Including BRAF-Mutated Melanoma, With Favorable Safety And Pharmacokinetics In Ongoing Phase 1 Dose Escalation Trial
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors ---- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who
06-02 20:14
